Phase I exploratory clinical study of CD276-targeted chimeric antigen receptor T cells for the treatment of solid tumors

ABSTRACT: Interventions: experimental group:CD276-targeted chimeric antigen receptor T cells Primary outcome(s): SAE rate Study Design: Single arm

DISEASE(S): Solid Tumors Mainly Include But Are Not Limited To Advanced Lung Cancer, Esophageal Cancer And Colorectal Cancer

PROVIDER: 2703905 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR